{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:14:07Z","timestamp":1791328447120,"version":"4.3.1"},"reference-count":17,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this study was to investigate the therapeutic effects of combined bumetanide and applied behavior analysis (ABA) treatment in children with autism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Sixty children diagnosed with autism according to the International Classification of Diseases, Tenth Revision (ICD-10) criteria (mean age of 4.5 years) were randomly divided into two groups: A single treatment group (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =28) and a combined treatment group (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =32). The combined treatment group received ABA training combined with oral bumetanide (0.5\u2009mg twice a day). The single treatment group received ABA training only. Autism symptoms were evaluated with the Autism Behavior Checklist (ABC) and the Childhood Autism Rating Scale (CARS), whereas severity of disease (SI) and global improvement (GI) were measured with the Clinical Global Impressions (CGI). Assessment of ABC, CARS, and CGI was performed immediately before and 3 months after initiation of the treatment(s).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Prior to intervention(s) no statistically significant differences in scores on the ABC, CARS, SI, or GI were found between the two groups. Total scores of the ABC, CARS, and SI were decreased in both groups after 3 months (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;0.05) compared with the scores prior to treatment. The total scores of the ABC and the CGI were significantly (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      &lt;0.05) lower in the combined treatment group than in the single treatment group. Although the total and item scores of the CARS in the combined treatment group were lower than in the single treatment group after a 3 month intervention, they did not reach statistical significance. No adverse effects of bumetanide were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Treatment with bumetanide combined with ABA training may result in a better outcome in children with autism than ABA training alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2015.0045","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T11:06:55Z","timestamp":1439204815000},"page":"585-588","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":78,"title":["A Pilot Study on the Combination of Applied Behavior Analysis and Bumetanide Treatment for Children with Autism"],"prefix":"10.1177","volume":"25","author":[{"given":"Lin","family":"Du","sequence":"first","affiliation":[{"name":"The First Hospital of Jilin University","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Shan","sequence":"additional","affiliation":[{"name":"The First Hospital of Jilin University","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Hospital of Jilin University","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghua","family":"Li","sequence":"additional","affiliation":[{"name":"The First Hospital of Jilin University","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhida","family":"Xu","sequence":"additional","affiliation":[{"name":"University Medical Center","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter G.","family":"Staal","sequence":"additional","affiliation":[{"name":"University Center","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyong","family":"Jia","sequence":"additional","affiliation":[{"name":"The First Hospital of Jilin University","place":["China"]},{"name":"Institute of Pediatrics of First Hospital of Jilin University","place":["China"]},{"name":"Neurological Research Center of First Hospital of Jilin University","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,9,1]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-013-1832-9"},{"key":"e_1_3_2_3_1","first-page":"28","article-title":"The clinical global impressions scale: Applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","unstructured":"Busner J, , Targum SD: The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry (Edgmont), 4:28\u201337, 2007.","journal-title":"Psychiatry (Edgmont)"},{"issue":"70","key":"e_1_3_2_4_1","article-title":"GABAergic signaling as therapeutic target for autism spectrum disorders","volume":"2","author":"Cellot G","year":"2014","unstructured":"Cellot G, , Cherubini E. GABAergic signaling as therapeutic target for autism spectrum disorders. Front Pediatr, 2:70, 2014.","journal-title":"Front Pediatr"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1301"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.161.4.343"},{"key":"e_1_3_2_7_1","article-title":"Risperidone for autism spectrum disorder","volume":"24","author":"Jesner OS","year":"2007","unstructured":"Jesner OS, , Aref\u2013Adib M, , Coren E.:Risperidone for autism spectrum disorder. Cochrane Database Syst Rev, 24:CD005040, 2007.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/892784"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2010.01933.x"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.124"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1516-44462005000400008"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2362"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1152\/jn.90761.2008"},{"key":"e_1_3_2_14_1","volume-title":"Part IV: Clinical Syndromes, 46 Autism Spectrum Disorders","author":"Rutter M","year":"2011","unstructured":"Rutter M, , Bishop D, , Pine D, , Scott, , Scott S, , Stevenson J, , Taylor E, , Thapar A: Rutter's Child and Adolescent Psychiatry, 5th ed. Part IV: Clinical Syndromes, 46 Autism Spectrum Disorders. Hoboken, NJ: John Wiley & Sons, 2011.","edition":"5"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedhc.2011.02.008"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.2298\/SARH1204236S"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1247190"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03391777"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2015.0045","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2015.0045","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2015.0045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:56:35Z","timestamp":1777388195000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2015.0045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1089\/cap.2015.0045"],"URL":"https:\/\/doi.org\/10.1089\/cap.2015.0045","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}